Terms: = Lymphoma AND ERC1, ELKS, 23085, ENSG00000082805, MGC12974, RAB6IP2, KIAA1081, Cast2, Q8IUD2, KIAA108
3 results:
1. Successful Crizotinib-targeted Therapy of Pediatric Unresectable erc1::ALK Fusion Sarcoma.
Wood ML; Fanburg-Smith JC; Brian JM; White JC; Powell JL; Freiberg AS
J Pediatr Hematol Oncol; 2024 Mar; 46(2):e184-e187. PubMed ID: 38099690
[TBL] [Abstract] [Full Text] [Related]
2. Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Zhou X; Shou J; Sheng J; Xu C; Ren S; Cai X; Chu Q; Wang W; Zhen Q; Zhou Y; Li W; Pan H; Li H; Sun T; Cheng H; Wang H; Lou F; Rao C; Cao S; Pan H; Fang Y
Cancer Sci; 2019 Oct; 110(10):3382-3390. PubMed ID: 31444835
[TBL] [Abstract] [Full Text] [Related]
3. Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes.
Couëtoux du Tertre M; Marques M; Tremblay L; Bouchard N; Diaconescu R; Blais N; Couture C; Pelsser V; Wang H; Higenell V; Izzi L; Gambaro K; Hoffert C; Srivastava A; Spatz A; Rousseau C; McNamara S; Cohen V; Batist G; Agulnik J
Mol Cancer Ther; 2019 Sep; 18(9):1628-1636. PubMed ID: 31243098
[TBL] [Abstract] [Full Text] [Related]
